Kite Pharma, Inc. (NASDAQ:KITE) reported Q2 2017 earnings this Morning, coming in at ($1.94) per share, missing Wall Street’s estimates of ($1.40) per Share. Revenue for the quarter came in at $10.10 million missing the streets estimates of $9.59 million
Analyst Coverage For Kite Pharma, Inc. (NASDAQ:KITE)
These are 1 Sell Rating, 6 Hold Ratings, 10 Buy Ratings .
The current consensus rating for Kite Pharma, Inc. (NASDAQ:KITE) is Buy (Score: 2.53) with a consensus target price of $87.25 , a potential (23.16% downside)Recent Insider Trading for Kite Pharma, Inc. (NASDAQ:KITE)
- On 8/3/2017 Timothy L Moore, EVP, sold 6,000 with an average share price of $110.06 per share and the total transaction amounting to $660,360.00.
- On 8/1/2017 Timothy L Moore, EVP, sold 12,000 with an average share price of $107.69 per share and the total transaction amounting to $1,292,280.00.
- On 7/31/2017 Helen Susan Kim, EVP, sold 26,649 with an average share price of $109.28 per share and the total transaction amounting to $2,912,202.72.
- On 7/10/2017 Cynthia M Butitta, COO, sold 15,000 with an average share price of $103.09 per share and the total transaction amounting to $1,546,350.00.
- On 7/3/2017 Jeffrey Wiezorek, SVP, sold 10,000 with an average share price of $104.32 per share and the total transaction amounting to $1,043,200.00.
- On 6/26/2017 Owen N Witte, Director, sold 25,000 with an average share price of $100.30 per share and the total transaction amounting to $2,507,500.00.
Recent Trading for Kite Pharma, Inc. (NASDAQ:KITE) Shares of Kite Pharma, Inc. closed the previous trading session at 119.90 up +6.35 5.59% with 865,013 shares trading hands.